Based on the available info, this event is deemed to be a serious injury based on the pt requiring prescription diflucan and prescription nystop powder.In addition, end-user performed skin prep; applied athletes foot powder and tinactin for treatment.No additional patient/event details have been provided to date.A return sample for evaluation is not expected.Should additional info become available, a follow-up report will be submitted.Convatec will continue to track and monitor such complainants according to convatec inc's.Complaint handling and capa procedures.
|
Corrected data: the following conclusions codes were previously omitted or reported in error on the initial mdr, mfr #: 1049092-2014-00264, reported to the fda on july 02, 2014: (b)(4).The product associated with batch (b)(4) was made according to specification.After detailed batch review, no discrepancies (includes non-conformances/deviations) were found.This complaint is not associated with a product malfunction.The complaint/incidence data-post market data analysis (trend analysis), clinical review, root cause analysis and risk assessment indicate a consistent rate of complaints as a result of skin complications which are caused by a variety of external factors not related to the design, materials, and/or processes of the product.No further actions are required, and this complaint will be closed.Product monitoring reviews will monitor for product trends if this issue were to reoccur.No additional patient/event details have been provided to date.Should additional information become available a follow-up report will be submitted.Reported to the fda on march 30, 2016, (b)(4).
|